• Journal Article

Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada

Citation

Earnshaw, S., Moride, Y., & Rochon, S. (2007). Cost-effectiveness of pegaptanib compared to photodynamic therapy with verteporfin and to standard care in the treatment of subfoveal wet age-related macular degeneration in Canada. Clinical Therapeutics, 29(9), 2096-2106.

Abstract